Abbott Laboratories (NYSE: ABT) is set to announce its fourth-quarter earnings on January 22, 2026, prior to the market opening. Analysts anticipate that the Abbott Park, Illinois-based company will report earnings of $1.49 per share, an increase from $1.34 per share during the same period last year. The projected quarterly revenue is $11.8 billion, up from $10.97 billion reported in the previous year, according to data from Benzinga Pro.
In a positive development for the company, Abbott received the CE Mark for its TactiFlex™ Duo Ablation Catheter on January 20, 2026. This catheter is designed to treat patients experiencing abnormal heart rhythms, potentially expanding Abbott’s product offerings in the cardiac care sector. Despite this news, Abbott’s stock experienced a slight decline, closing at $120.73, down 0.3% on the previous Wednesday.
Analyst Ratings Show Optimism
Recent analyst ratings reflect a generally optimistic outlook for Abbott. On January 9, 2026, Lee Hambright, an analyst at Bernstein, maintained an Outperform rating and raised the price target from $150 to $154. Hambright has an accuracy rate of 60% based on his past predictions.
Similarly, Matt Miksic from Barclays kept an Overweight rating while adjusting the price target upward from $162 to $169 on January 5, 2026. Miksic has demonstrated a higher accuracy rate of 65% in his assessments.
On November 20, 2025, Marie Thibault from BTIG maintained a Buy rating with a price target of $145, showing consistent confidence in Abbott’s performance. Thibault’s accuracy rate also stands at 60%.
Further affirming the positive sentiment, Jayson Bedford of Raymond James raised his price target from $141 to $146 on October 16, 2025, maintaining an Outperform rating with an accuracy rate of 66%. Meanwhile, Vijay Kumar from Evercore ISI Group adjusted his price target from $144 to $142, continuing to endorse an Outperform rating as of the same date.
As Abbott approaches its earnings report, the adjustments made by Wall Street analysts highlight a cautious yet optimistic outlook for the company’s financial health. Investors and market watchers will be keenly observing the upcoming earnings announcement for further insights into Abbott’s performance and future growth prospects.
